Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMP-110 in Rheumatoid Arthritis
NCT02277574Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jun 2014
- Primary completion
- Jan 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMP-110 in rheumatoid arthritis (RA), sponsored by MedImmune. Primary endpoint: Number of Adverse Events at 112 days. Started Jun 2014; status: completed.
02
Drugs
AMP-110
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02277574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277574.